Hulk Hogan, wrestling icon, dies at 71 in Florida home
On Tuesday, Stifel maintained its Hold rating on shares of Givaudan SA (GIVN:SW) (OTC: GVDNY), with a consistent price target of CHF4,200.00. Givaudan, the Swiss manufacturer of flavors and fragrances, reported its first-half 2024 adjusted EBITDA at CHF 929 million, surpassing the consensus estimate of CHF 907 million by more than 2%. This figure also closely matched Stifel's own forecast of CHF 922 million.
The company's adjusted EBITDA margin for the first half stood at 24.9%, which was higher than the consensus of 24.3% and slightly above Stifel's prediction of 24.5%. Givaudan's organic growth for the second quarter was reported at 12.3%, aligning with the market consensus of 12.8% and narrowly missing Stifel's estimate of 13.1%.
Givaudan experienced a sequential acceleration in volume, with a year-over-year increase of 9.7% for the second quarter, compared to 8.6% in the first quarter. The pricing rose by 2.6%, primarily due to the impact of Latin American dollar pricing effects. The company has noted that it continues to experience strong business momentum and maintains a robust project pipeline.
Despite these positive indicators, Stifel views the departure of Givaudan's CFO, Tom Hallam, as a slight negative. Hallam is recognized for his significant contributions to the company's operational performance and his effective communication with capital markets. The firm's stance reflects the belief that his leaving may have an impact on the company's future performance.
In other recent news, Givaudan, a leader in the flavor and fragrance industry, has received updated ratings from Barclays and Deutsche Bank.
Barclays has shifted its rating from Underweight to Equalweight and increased the price target to CHF4,000, citing a more optimistic outlook for the Fine Fragrances sector and Givaudan's strong performance momentum. The firm's analysis suggests that Givaudan's earnings before interest, taxes, depreciation, and amortization (EBITDA) for 2024 and 2025 may exceed consensus estimates.
Meanwhile, Deutsche Bank has raised its price target on Givaudan's shares from CHF 4,000 to CHF 4,350, maintaining a Hold rating. This adjustment is based on expected increases in sales growth and profit margins. The bank's revised model predicts a rise in Givaudan's earnings per share (EPS) forecasts for the years 2024-2026 by 4-6%.
Furthermore, Deutsche Bank has increased its margin assumptions for Givaudan by an average of 30 basis points over the next three years. The bank also expects a reduced negative impact from foreign exchange rates, adjusting the estimate to a 2% detriment compared to the former 4.2% figure.
These recent developments reflect the latest analysis of Givaudan's financial prospects and market position.
InvestingPro Insights
Givaudan SA's recent performance has been commendable, with a notable adjusted EBITDA exceeding consensus estimates. To further understand the company's financial health and investment potential, we turn to real-time data and insights from InvestingPro. With a market capitalization of $42.99 billion and a high P/E ratio of 42.87, Givaudan trades at a significant earnings multiple, which suggests investor confidence in its future growth, despite a slight decline in revenue growth over the last twelve months.
InvestingPro Tips highlight that Givaudan has a strong track record of dividend reliability, having raised its dividend for 15 consecutive years and maintained payments for 24 years. Additionally, the company's stock generally exhibits low price volatility, providing a degree of stability for investors. The stock is trading near its 52-week high, with a price percentage of 98.43% of that peak, indicating strong market sentiment.
For readers interested in a deeper dive into Givaudan's investment profile, there are 13 additional InvestingPro Tips available at https://www.investing.com/pro/GVDNY. These insights can be accessed with a special offer: use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, providing valuable context for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.